The human epidermal growth factor receptor 2 positive (HER2+) breast cancer subtype makes up 15–20% of breast cancers, with approximately 70% of HER2+ breast cancers also classed as oestrogen receptor α positive (ER+) [1]. This evidence concerns the gene ESR1 and breast carcinoma.